Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells

Endocrinology. 2004 May;145(5):2141-7. doi: 10.1210/en.2003-1229. Epub 2004 Jan 28.

Abstract

The nicotinamide adenine dinucleotide-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes the oxidation of 15 (S)-hydroxyl group of prostaglandins and lipoxins and participates along with cyclooxygenases and lipoxygenases in controlling the cellular levels of prostaglandins and lipoxins. 15-PGDH could be induced by IL-6 and forskolin in addition to androgens in a time- and dose-dependent manner but not by other cytokines and growth factors in LNCaP cells. Concurrent addition of IL-6 and forskolin showed additive effect in the induction of 15-PGDH activity. However, combined addition of dihydrotestosterone (DHT) and IL-6 or DHT plus forskolin exhibited synergistic induction of 15-PGDH activity. The increase in enzyme activity was correlated with the expression of the enzyme protein as shown by Western blot analysis. The induction by DHT or IL-6 or forskolin or their combinations was inhibited by antiandrogen, casodex, in a dose-dependent manner, indicating that a functional androgen receptor was required for the action of any of these three agents. The induction by forskolin plus DHT or by either agent or by IL-6 alone was greatly inhibited by H-89, indicating the involvement of protein kinase A in the actions of forskolin, DHT, and IL-6. The induction of 15-PGDH by IL-6 was also blocked by some other protein kinase inhibitors, indicating the participation of MAPK, MAPK/ERK kinase, and STAT3 in the signaling pathway of IL-6. These results indicate that the induction of 15-PGDH by DHT, IL-6, and forskolin in LNCaP cells may involve a functional androgen receptor and phosphorylation-dependent multiple signaling pathways.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Androgen Antagonists / pharmacology
  • Anilides / pharmacology
  • Blotting, Western
  • Colforsin / pharmacology*
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • DNA-Binding Proteins / metabolism
  • Dihydrotestosterone / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Enzyme Induction / drug effects
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Hydroxyprostaglandin Dehydrogenases / biosynthesis*
  • Interleukin-6 / pharmacology*
  • Isoquinolines / pharmacology
  • Kinetics
  • Male
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase Kinases / metabolism
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Mitogen-Activated Protein Kinases / metabolism
  • Nitriles
  • Phosphorylation
  • Prostatic Neoplasms / enzymology*
  • Receptors, Androgen / physiology
  • STAT3 Transcription Factor
  • Signal Transduction
  • Sulfonamides*
  • Tosyl Compounds
  • Trans-Activators / metabolism
  • Tumor Cells, Cultured

Substances

  • Androgen Antagonists
  • Anilides
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • Interleukin-6
  • Isoquinolines
  • Nitriles
  • Receptors, Androgen
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Sulfonamides
  • Tosyl Compounds
  • Trans-Activators
  • Dihydrotestosterone
  • Colforsin
  • bicalutamide
  • Hydroxyprostaglandin Dehydrogenases
  • 15-hydroxyprostaglandin dehydrogenase
  • Cyclic AMP-Dependent Protein Kinases
  • Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase Kinases
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide